beta

ALIM

Alimera Sciences Inc.

Alim

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

11-05-2018 after market close 07-30-2018 after market close 05-03-2018 02-28-2018 after market close 11-01-2017 after market close 08-02-2017 after market close 05-08-2017 after market close
Actual EPS -0.05 -0.06 -0.08 -0.1 -0.04 -0.04 -0.1
Consensus EPS -0.06 -0.06 -0.06 -0.05 -0.05 -0.07 -0.08
Estimated EPS -0.06 -0.06 -0.06 -0.05 -0.05 -0.07 -0.08
Number of Estimates 3 3 2 2 2 2 2
EPS Surprise $0.01 -$0.02 -$0.05 $0.01 $0.03 -$0.02

Stats

Summary

Alimera Sciences Inc is a biopharmaceutical company which is engaged in the research, development, and commercialization of ophthalmic pharmaceuticals.

Market Cap: 82.3 Million

Primary Exchange: NASDAQ Global Market

Website: http://www.alimerasciences.com

Shares Outstanding: 69.1 Million

Float: 68.4 Million

Dividend: 0.0 (0.0%)

Beta: 1.787559

Sector: Healthcare

Industry: Drug Manufacturers

Short Interest (Jan 12, 2018): 697 Thousand

Ethical Flags

Animal testing

Longest drawdown: 1180 trading days

From: 2014-03-31 To: 2018-12-14

Lowest Point:

Alimera Sciences, Inc. (ALIM) CEO Dan Myers on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-06 11:50:58:000

Alimera Sciences, Inc. (ALIM) Q3 2018 Results Earnings Conference Call November 6, 2018 9:00 AM ET Executives Jacob Goldberger Investor Relations, Analyst at CG Capital Dan Myers Chief Executive Officer Rick Eiswirth President and Chief Financial Office… read more...

Alimera Sciences, Inc. (ALIM) CEO Dan Myers on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-06 11:50:58:000

Alimera Sciences, Inc. (ALIM) Q3 2018 Results Earnings Conference Call November 6, 2018 9:00 AM ET Executives Jacob Goldberger Investor Relations, Analyst at CG Capital Dan Myers Chief Executive Officer Rick Eiswirth President and Chief Financial Office… read more...

Alimera Sciences, Inc. (ALIM) CEO Dan Myers on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-11-06 11:50:58:000

Alimera Sciences, Inc. (ALIM) Q3 2018 Results Earnings Conference Call November 6, 2018 9:00 AM ET Executives Jacob Goldberger Investor Relations, Analyst at CG Capital Dan Myers Chief Executive Officer Rick Eiswirth President and Chief Financial Office… read more...

FDA nod for EyePoint's Yutiq eye implant fails to lift shares, down almost a third since approval

via: SeekingAlpha at 2018-10-19 11:57:59:000

EyePoint Pharmaceuticals ( EYPT -12.9% ) continues its slide despite FDA approval earlier this week for YUTIQ (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious uveitis. Shares have sold off 32% since touching $3.78 on Tuesday. More news… read more...

FDA nod for EyePoint's Yutiq eye implant fails to lift shares, down almost a third since approval

via: SeekingAlpha at 2018-10-19 11:57:59:000

EyePoint Pharmaceuticals ( EYPT -12.9% ) continues its slide despite FDA approval earlier this week for YUTIQ (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious uveitis. Shares have sold off 32% since touching $3.78 on Tuesday. More news… read more...

FDA nod for EyePoint's Yutiq eye implant fails to lift shares, down almost a third since approval

via: SeekingAlpha at 2018-10-19 11:57:59:000

EyePoint Pharmaceuticals ( EYPT -12.9% ) continues its slide despite FDA approval earlier this week for YUTIQ (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious uveitis. Shares have sold off 32% since touching $3.78 on Tuesday. More news… read more...

FDA nod for EyePoint's Yutiq eye implant fails to lift shares, down almost a third since approval

via: SeekingAlpha at 2018-10-19 11:57:59:000

EyePoint Pharmaceuticals ( EYPT -12.9% ) continues its slide despite FDA approval earlier this week for YUTIQ (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious uveitis. Shares have sold off 32% since touching $3.78 on Tuesday. More news… read more...

FDA nod for EyePoint's Yutiq eye implant fails to lift shares, down almost a third since approval

via: SeekingAlpha at 2018-10-19 11:57:59:000

EyePoint Pharmaceuticals ( EYPT -12.9% ) continues its slide despite FDA approval earlier this week for YUTIQ (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious uveitis. Shares have sold off 32% since touching $3.78 on Tuesday. More news… read more...

Alimera Sciences Announces Nine Clinical Presentations and a Sponsored Symposium at 18th EURETINA Congress

via: PR Newswire at 2018-09-17 17:32:00:000

ATLANTA , Sept. 17, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in commercialization and development of prescription ophthalmic pharmaceuticals, today announced that nine clinical presentations from real world ILUVIEN usage in Europe and t… read more...

Alimera Sciences Announces Nine Clinical Presentations and a Sponsored Symposium at 18th EURETINA Congress

via: PR Newswire at 2018-09-17 17:32:00:000

ATLANTA , Sept. 17, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in commercialization and development of prescription ophthalmic pharmaceuticals, today announced that nine clinical presentations from real world ILUVIEN usage in Europe and t… read more...

Alimera Sciences Announces Nine Clinical Presentations and a Sponsored Symposium at 18th EURETINA Congress

via: PR Newswire at 2018-09-17 17:32:00:000

ATLANTA , Sept. 17, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in commercialization and development of prescription ophthalmic pharmaceuticals, today announced that nine clinical presentations from real world ILUVIEN usage in Europe and t… read more...

Alimera Sciences Announces Three Podium Presentations for ILUVIEN® to be Presented at 2018 Retina Society's Annual Meeting

via: PR Newswire at 2018-09-13 16:30:00:000

ATLANTA , Sept. 13, 2018 /PRNewswire/ --Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that two presentations will be delivered, and one poster presented, on ILUVIEN &#xAE… read more...

Alimera Sciences Announces Three Podium Presentations for ILUVIEN® to be Presented at 2018 Retina Society's Annual Meeting

via: PR Newswire at 2018-09-13 16:30:00:000

ATLANTA , Sept. 13, 2018 /PRNewswire/ --Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that two presentations will be delivered, and one poster presented, on ILUVIEN &#xAE… read more...

Alimera Sciences Announces Three Podium Presentations for ILUVIEN® to be Presented at 2018 Retina Society's Annual Meeting

via: PR Newswire at 2018-09-13 16:30:00:000

ATLANTA , Sept. 13, 2018 /PRNewswire/ --Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that two presentations will be delivered, and one poster presented, on ILUVIEN &#xAE… read more...

Alimera Sciences Announces Exchange of Series B Preferred Stock for Newly Issued Series C Preferred Stock

via: PR Newswire at 2018-09-04 17:43:00:000

ATLANTA , Sept. 4, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it has closed an agreement with Deerfield Management and certain of its affiliates (D… read more...

Alimera Sciences Announces Exchange of Series B Preferred Stock for Newly Issued Series C Preferred Stock

via: PR Newswire at 2018-09-04 17:43:00:000

ATLANTA , Sept. 4, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it has closed an agreement with Deerfield Management and certain of its affiliates (D… read more...

Alimera Sciences Announces Exchange of Series B Preferred Stock for Newly Issued Series C Preferred Stock

via: PR Newswire at 2018-09-04 17:43:00:000

ATLANTA , Sept. 4, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it has closed an agreement with Deerfield Management and certain of its affiliates (D… read more...

Alimera Sciences to Present at the 20th Annual HC Wainwright Global Investment Conference

via: PR Newswire at 2018-08-29 07:30:00:000

ATLANTA , Aug. 29, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers , Chief Executive Officer, will be presenting at t… read more...

Alimera Sciences to Present at the 20th Annual HC Wainwright Global Investment Conference

via: PR Newswire at 2018-08-29 07:30:00:000

ATLANTA , Aug. 29, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers , Chief Executive Officer, will be presenting at t… read more...

Alimera Sciences to Present at the 20th Annual HC Wainwright Global Investment Conference

via: PR Newswire at 2018-08-29 07:30:00:000

ATLANTA , Aug. 29, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers , Chief Executive Officer, will be presenting at t… read more...

Alimera Sciences to Present at the Annual B. Riley Healthcare Conference

via: PR Newswire at 2018-08-28 07:30:00:000

ATLANTA , Aug. 28, 2018 /PRNewswire/ -- Alimera Sciences (NASDAQ: ALIM), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers , Chief Executive Officer, will be presenting at t… read more...

Alimera Sciences, Inc. 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-08-01 14:42:40:000

The following slide deck was published by Alimera Sciences, Inc. in conjunction with their 2018 Q2 earnings Read more … read more...

Alimera Sciences, Inc. 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-08-01 14:42:40:000

The following slide deck was published by Alimera Sciences, Inc. in conjunction with their 2018 Q2 earnings Read more … read more...

Alimera Sciences, Inc. 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-08-01 14:42:40:000

The following slide deck was published by Alimera Sciences, Inc. in conjunction with their 2018 Q2 earnings Read more … read more...

Alimera Sciences, Inc. (ALIM) CEO Dan Myers on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-31 11:09:05:000

Alimera Sciences, Inc. (ALIM) Q1 2018 Results Earnings Conference Call July 31, 2018, 9:00 am ET Executives Jacob Goldberger - Investor Relations, Analyst at CG Capital Dan Myers - Chief Executive Officer Rick Eiswirth - President and Chief Financial Officer Analysts Andrew… read more...

Alimera Sciences EPS in-line, beats on revenue

via: SeekingAlpha at 2018-07-30 16:34:48:000

Alimera Sciences (NASDAQ: ALIM ): Q2 EPS of -$0.06 in-line. More news on: Alimera Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Alimera Sciences Reports Second Quarter 2018 Results

via: PR Newswire at 2018-07-30 16:30:00:000

ATLANTA , July 30, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced financial results for the three months ended June… read more...

Alimera Sciences to Report Second Quarter 2018 Results July 30, 2018

via: PR Newswire at 2018-07-18 07:30:00:000

ATLANTA , July 18, 2018 /PRNewswire/ --Alimera Sciences (NASDAQ: ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the second quarter ended June 30, 2018 , after the cl… read more...

Alimera Sciences to Report Second Quarter 2018 Results July 30, 2018

via: PR Newswire at 2018-07-18 07:30:00:000

ATLANTA , July 18, 2018 /PRNewswire/ --Alimera Sciences (NASDAQ: ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the second quarter ended June 30, 2018 , after the cl… read more...

Alimera Sciences to Report Second Quarter 2018 Results July 30, 2018

via: PR Newswire at 2018-07-18 07:30:00:000

ATLANTA , July 18, 2018 /PRNewswire/ --Alimera Sciences (NASDAQ: ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the second quarter ended June 30, 2018 , after the cl… read more...

Alimera Sciences Announces 8 ILUVIEN® Presentations At The 2018 American Society Of Retina Specialists Annual Meeting

via: PR Newswire at 2018-07-11 07:30:00:000

ATLANTA , July 11, 2018 /PRNewswire/ --Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that 8 presentations on ILUVIEN data have been accepted during the 36 th Annual Meet… read more...

Alimera Sciences Announces 8 ILUVIEN® Presentations At The 2018 American Society Of Retina Specialists Annual Meeting

via: PR Newswire at 2018-07-11 07:30:00:000

ATLANTA , July 11, 2018 /PRNewswire/ --Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that 8 presentations on ILUVIEN data have been accepted during the 36 th Annual Meet… read more...

Alimera Sciences Announces 8 ILUVIEN® Presentations At The 2018 American Society Of Retina Specialists Annual Meeting

via: PR Newswire at 2018-07-11 07:30:00:000

ATLANTA , July 11, 2018 /PRNewswire/ --Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that 8 presentations on ILUVIEN data have been accepted during the 36 th Annual Meet… read more...

Alimera Sciences Appoints Mary T. Szela to its Board of Directors

via: PR Newswire at 2018-06-21 07:30:00:000

ATLANTA , June 21, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced Mary T. Szela has joined its Board of Directors. Ms. Szela is currently the Chief … read more...

Alimera Sciences Appoints Mary T. Szela to its Board of Directors

via: PR Newswire at 2018-06-21 07:30:00:000

ATLANTA , June 21, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced Mary T. Szela has joined its Board of Directors. Ms. Szela is currently the Chief … read more...

The UK National Institute For Health And Care Excellence To Undertake A Partial Review Of The ILUVIEN Reimbursement Guidance Allowing Broader Availability

via: PR Newswire at 2018-06-11 07:30:00:000

ATLANTA , June 11, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom (UK) National Institute for H… read more...

The UK National Institute For Health And Care Excellence To Undertake A Partial Review Of The ILUVIEN Reimbursement Guidance Allowing Broader Availability

via: PR Newswire at 2018-06-11 07:30:00:000

ATLANTA , June 11, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom (UK) National Institute for H… read more...

The UK National Institute For Health And Care Excellence To Undertake A Partial Review Of The ILUVIEN Reimbursement Guidance Allowing Broader Availability

via: PR Newswire at 2018-06-11 07:30:00:000

ATLANTA , June 11, 2018 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom (UK) National Institute for H… read more...

Alimera Sciences Terminates At-the-Market Offering Agreement

via: PR Newswire at 2018-06-04 07:30:00:000

ATLANTA , June 4, 2018 /PRNewswire/ --Alimera Sciences (NASDAQ: ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it has terminated its October 2017 agreement for an investment bank to sell, at the company's r… read more...

Alimera Sciences Terminates At-the-Market Offering Agreement

via: PR Newswire at 2018-06-04 07:30:00:000

ATLANTA , June 4, 2018 /PRNewswire/ --Alimera Sciences (NASDAQ: ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it has terminated its October 2017 agreement for an investment bank to sell, at the company's r… read more...

Alimera Sciences Terminates At-the-Market Offering Agreement

via: PR Newswire at 2018-06-04 07:30:00:000

ATLANTA , June 4, 2018 /PRNewswire/ --Alimera Sciences (NASDAQ: ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it has terminated its October 2017 agreement for an investment bank to sell, at the company's r… read more...

Alimera Sciences Announces the Reimbursement of ILUVIEN® in Spain

via: PR Newswire at 2018-05-31 07:30:00:000

ATLANTA , May 31, 2018 /PRNewswire/ --Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that its subsidiary, Alimera Sciences Limited, received a positive resolution for the … read more...

Alimera Sciences Announces the Reimbursement of ILUVIEN® in Spain

via: PR Newswire at 2018-05-31 07:30:00:000

ATLANTA , May 31, 2018 /PRNewswire/ --Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that its subsidiary, Alimera Sciences Limited, received a positive resolution for the … read more...

Alimera Sciences Announces the Reimbursement of ILUVIEN® in Spain

via: PR Newswire at 2018-05-31 07:30:00:000

ATLANTA , May 31, 2018 /PRNewswire/ --Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that its subsidiary, Alimera Sciences Limited, received a positive resolution for the … read more...

Alimera Sciences to Present at the 8th Annual LD Micro Invitational Conference

via: PR Newswire at 2018-05-22 07:30:00:000

ATLANTA , May 22, 2018 /PRNewswire/ --Alimera Sciences (NASDAQ: ALIM), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that CEO Dan Myers will be presenting at the 8 th annual LD Micro Invitational Conference taking pl… read more...

Alimera Sciences' (ALIM) CEO Dan Myers on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-06 07:19:04:000

Alimera Sciences, Inc. (ALIM) Q1 2018 Results Earnings Conference Call May 3, 2018, 10:00 AM ET Executives Jacob Goldberger - CG Capital Dan Myers - CEO Rick Eiswirth - President and CFO Analysts Andrew D'Silva - B. Riley FBR Franois Brisebois - Laidlaw & Compan… read more...

Alimera Sciences' (ALIM) CEO Dan Myers on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-06 07:19:04:000

Alimera Sciences, Inc. (ALIM) Q1 2018 Results Earnings Conference Call May 3, 2018, 10:00 AM ET Executives Jacob Goldberger - CG Capital Dan Myers - CEO Rick Eiswirth - President and CFO Analysts Andrew D'Silva - B. Riley FBR Franois Brisebois - Laidlaw & Compan… read more...

Alimera Sciences, Inc. 2018 Q1 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-05-04 13:55:27:000

The following slide deck was published by Alimera Sciences, Inc. in conjunction with their 2018 Q1 earnings Read more … read more...

Alimera Sciences, Inc. 2018 Q1 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-05-04 13:55:27:000

The following slide deck was published by Alimera Sciences, Inc. in conjunction with their 2018 Q1 earnings Read more … read more...

Alimera Sciences misses by $0.05, misses on revenue

via: SeekingAlpha at 2018-05-02 16:44:22:000

Alimera Sciences (NASDAQ: ALIM ): Q1 EPS of -$0.11 misses by $0.05 . More news on: Alimera Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Alimera Sciences misses by $0.05, misses on revenue

via: SeekingAlpha at 2018-05-02 16:44:22:000

Alimera Sciences (NASDAQ: ALIM ): Q1 EPS of -$0.11 misses by $0.05 . More news on: Alimera Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

FDA OKs AI software to detect diabetic retinopathy

via: SeekingAlpha at 2018-04-11 12:51:05:000

Under its De Novo (no predicate product) review pathway, the FDA approves the first medical device in the U.S. that uses artificial intelligence (AI) to perform its designated function. The device, called IDx-DR, is a software program used to detect greater than a mild level of diabetic re… read more...

FDA OKs AI software to detect diabetic retinopathy

via: SeekingAlpha at 2018-04-11 12:51:05:000

Under its De Novo (no predicate product) review pathway, the FDA approves the first medical device in the U.S. that uses artificial intelligence (AI) to perform its designated function. The device, called IDx-DR, is a software program used to detect greater than a mild level of diabetic re… read more...

Alimera Sciences' (ALIM) CEO Dan Myers on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-03-01 12:48:06:000

Alimera Sciences, Inc. (ALIM) Q4 2017 Earnings Conference Call March 1, 2018 9:00 A.M. ET Executives Jacob Goldberger - CG Capital Dan Myers - Chief Executive Officer Rick Eiswirth - President and Chief Financial Officer Analysts Franois Brisebois - Laidlaw & Comp… read more...

Alimera Sciences' (ALIM) CEO Dan Myers on Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-03-01 12:48:06:000

Alimera Sciences, Inc. (ALIM) Q4 2017 Earnings Conference Call March 1, 2018 9:00 A.M. ET Executives Jacob Goldberger - CG Capital Dan Myers - Chief Executive Officer Rick Eiswirth - President and Chief Financial Officer Analysts Franois Brisebois - Laidlaw & Comp… read more...

Alimera Sciences misses by $0.06, misses on revenue

via: SeekingAlpha at 2018-02-28 16:32:46:000

Alimera Sciences (NASDAQ: ALIM ): Q4 EPS of -$0.10 misses by $0.06 . Revenue of $9.14M (-14.4% Y/Y) misses by $3.03M . Press Release More news on: Alimera Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , read more...

Alimera Sciences misses by $0.06, misses on revenue

via: SeekingAlpha at 2018-02-28 16:32:46:000

Alimera Sciences (NASDAQ: ALIM ): Q4 EPS of -$0.10 misses by $0.06 . Revenue of $9.14M (-14.4% Y/Y) misses by $3.03M . Press Release More news on: Alimera Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , read more...

Notable earnings after Wednesday's close

via: SeekingAlpha at 2018-02-27 17:35:34:000

AEGN , ALEX , ALIM , AMBC , AXGN , BLDP , BLDR , BOX , CBPO , CCRN , CHDN , CODI , CRM , DCO , DDD , ECR , EPE , EPR , FOE , GEF , GKOS , GPT , GTY , HABT , HGV , HIIQ , HK , HLIT , ILG , ITRI , JCAP , KTOS , KTWO , KWR , LB , LHCG , LQ , MMSI , MNST ,… read more...

Notable earnings after Wednesday's close

via: SeekingAlpha at 2018-02-27 17:35:34:000

AEGN , ALEX , ALIM , AMBC , AXGN , BLDP , BLDR , BOX , CBPO , CCRN , CHDN , CODI , CRM , DCO , DDD , ECR , EPE , EPR , FOE , GEF , GKOS , GPT , GTY , HABT , HGV , HIIQ , HK , HLIT , ILG , ITRI , JCAP , KTOS , KTWO , KWR , LB , LHCG , LQ , MMSI , MNST ,… read more...

Alimera's European application for expanded use of Iluvien under review

via: SeekingAlpha at 2018-01-04 12:20:17:000

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) accepts for review Alimera Sciences ( ALIM +0.8% ) marketing application seeking approval to use ILUVIEN (fluocinolone acetonide intravitreal implant) to treat recurrent/persistent non-infectious uveitis affecting the po… read more...

Healthcare events next week

via: SeekingAlpha at 2017-12-01 13:44:04:000

Upcoming events in healthcare next week: More news on: Zogenix, Inc., Omnicell, Inc., Ultragenyx Pharmaceutical Inc., Healthcare stocks news, Read more … read more...

Alimera Sciences' (ALIM) CEO Dan Myers on Q3 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-11-03 22:49:19:000

Alimera Sciences Inc. (ALIM) Q3 2017 Results Earnings Conference Call November 2, 2017, 09:00 AM ET Executives Jacob Goldberger - CG Capital Dan Myers - CEO Rick Eiswirth - President and CFO Analysts Francois Brisebois - Laidlaw & Company Yi Chen - HC Wainwright Pr… read more...

CMS issues final list of therapies facing expiration of pass-through status for 2018

via: SeekingAlpha at 2017-11-02 15:30:45:000

The Centers for Medicare & Medicaid Services (CMS) has issued its final update on the therapies facing expiration of pass-through status in 2018. More news on: Omeros Corporation, Eli Lilly and Company, Astellas Pharma, Inc. ADR, Healthcare stocks news, Read more … read more...

Alimera Sciences, Inc. 2017 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2017-11-02 08:50:04:000

The following slide deck was published by Alimera Sciences, Inc. in conjunction with their 2017 Q3 earnings Read more … read more...

Alimera Sciences misses by $0.03, misses on revenue

via: SeekingAlpha at 2017-11-01 17:39:28:000

Alimera Sciences (NASDAQ: ALIM ): Q3 EPS of -$0.08 misses by $0.03 . Revenue of $9.8M (+18.1% Y/Y) misses by $0.88M . Press Release More news on: Alimera Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , read more...

Notable earnings after Wednesday's close

via: SeekingAlpha at 2017-10-31 17:35:44:000

AAC , ACXM , ADSW , AEGN , ALIM , ALL , ANSS , AR , ARC , AREX , ARI , ARRS , ATRC , AWK , AXGN , BBRG , BFAM , BGC , BLDP , BOJA , BXP , CACI , CAKE , CAVM , CBPO , CCRN , CF , CFMS , CHDN , CLVS , CMPR , CNAT , CSGS , CSU , CTRP , CWST , CYH , CZR , … read more...

Alimera Sciences' (ALIM) CEO Dan Myers on Q2 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-08-06 02:35:10:000

Alimera Sciences Inc. (ALIM) Q2 2017 Earnings Conference Call August 03, 2017 9:00 AM ET Executives Jacob Goldberger - CG Capital Dan Myers - Chief Executive Officer Rick Eiswirth - President and Chief Financial Officer Analysts Francois Brisebois - Laidlaw & Company … read more...

Alimera Sciences beats by $0.01, misses on revenue

via: SeekingAlpha at 2017-08-02 17:52:32:000

Alimera Sciences (NASDAQ: ALIM ): Q2 EPS of -$0.04 beats by $0.01 . More news on: Alimera Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Notable earnings after Wednesday's close

via: SeekingAlpha at 2017-08-01 17:35:56:000

AAC , ADSW , AEL , AGO , AIG , ALEX , ALIM , ANSS , APTI , APU , AR , AREX , ARRS , ATO , AVB , AWK , AWR , AXGN , AYX , BECN , BGC , BIVV , BKCC , BLDP , BMRN , BREW , BRKS , CA , CAKE , CATM , CAVM , CBPO , CC , CCRN , CENT , CENX , CF , CIM , CINF ,… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX